🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Goldman Sachs raises Eli Lilly 2030 GLP-1 medications forecast to $130bn

Published 05/30/2024, 11:46 AM
Updated 05/30/2024, 11:48 AM
© Reuters Goldman Sachs raises Eli Lilly (LLY) 2030 GLP-1 medications forecast to $130bn
LLY
-

Analysts at Goldman Sachs lifted their forecast for Eli Lilly & Co.'s (NYSE:LLY) total worldwide sales of next-generation, primarily GLP-1 receptor agonist anti-obesity medications to $130 billion in 2030 in a note Thursday.

This is up from the investment bank's prior forecast of $100 billion.

The updated forecast has prompted analysts to lift their price target for the stock to $785 per share from $740, with the firm maintaining a Neutral rating on the company's shares.

The update reflects Goldman Sachs' assessment of the impact of certain events that have occurred since its last published estimate, October 2023, across several key domains.

"For LLY, we now forecast revenues for the company's AOM portfolio (including the currently commercialized tirzepatide products Monjouro and Zepbound) in 2024/2027/2030 at $5.3bn, $27.6bn and $56.6bn, representing an increase from $4.7bn, $28.2bn and $49.7bn prior," added the bank.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.